A recent study focused on the role of FGF13 expression in triple negative breast cancer (TNBC) (ER-, progesterone receptor-, and human epidermal growth factor receptor 2 (HER2/ERBB2)-negative breast cancer), an aggressive subtype of breast cancer where FGF13 expression was associated with relapse but was not increased in primary breast tumors. This evidence concerns the gene ERBB2 and breast cancer.